The leading law firms Skadden and Ropes & Grey are offering legal advice on the buyout bid for 23andMe, the Californian genomics and biotechnology company. According to a source familiar with the matter, both law firms are providing their expertise to guide this proposed corporate manoeuvre.
Details regarding the value of the buyout bid or the potential buyer’s identity have been kept under wraps. These critical aspects of the deal are presently unknown to the public.
Skadden, known formally as Skadden, Arps, Slate, Meagher & Flom, has a long-established reputation in providing robust legal assistance for mergers and acquisitions. According to Chambers and Partners, Skadden ranks as one of the top five firms in mergers and acquisitions globally.
Similarly, Ropes & Gray, with its focus on complex transactions and cybersecurity, is equally adept in the realm of corporate law. They have a well-regarded private equity practice that enables them to guide such buyout bids.
The buyout of 23andMe, if successful, could result in significant changes in the genomics industry. The company is known for its direct-to-consumer DNA testing kits, a product that has found success in the general consumer market.
Representatives for 23andMe, Skadden, Arps, Slate, Meagher & Flom, and Ropes & Gray have yet to make a public statement about this ongoing transaction.
Last modified: March 2, 2025
